DNA and enzyme studies on chorionic villi for use in antenatal diagnosis

doi:10.1016/0009-8981(84)90149-9

Clinica Chimica Acta

Volume 140, Issue 1, 27 June 1984, Pages 39-46

https://doi.org/10.1016/0009-8981(84)90149-9 Get rights and content

Abstract

A study has been undertaken to determine the efficiency of current methods in providing an adequate amount of chorionic villus DNA for antenatal diagnosis using recombinant DNA techniques or enzyme assay. Chorionic biopsies were obtained from 40 women undergoing elective first trimester termination of pregnancy (8–12 weeks) under general anaesthesia. The villus tissue was isolated from maternal tissue under a dissection microscope and the presence of any remaining contamination was ascertained by conventional histology and immuno-cytochemical examinations. A high level of success was achieved in obtaining a pure fetal sample. In the first 20 samples the DNA yield obtained using the method of Williamson et al [1] was found to be 0.5 ± 0.5 μg/mg wet weight of villus tissue (mean ± 1 SD). In the subsequent 20 biopsies using a modified procedure, the yield was significantly improved to 1.0 ±0.65 (p < 0.002). A normal range for the enzyme iduronate sulphatase. which is deficient in Hunter's syndrome (mucopolysaccharidosis II). is also reported. It is suggested that as little as 20 mg of chorionic villi may be used to provide sufficient material for a reliable study using recombinant DNA or biochemical methods.

References (16)

R Williamson et al.
Direct gene analysis of chorionic villi: a possible technique for first trimester antenatal diagnosis of haemoglohinopathies
Lancet
(1981)
JM Old et al.
First trimester fetal diagnosis for haemoglobinopathies: three cases
Lancet
(1982)
JR Gosden et al.
Direct vision chorion biopsy and chromosome specific DNA probes for determination of fetal sex in first trimester prenatal diagnosis
Lancet
(1982)
IM Archer et al.
An improved assay for iduronate 2-sulphate sulphatase in serum and its use in the detection of carriers of Hunter syndrome
Clin Chim Acta
(1981)
OH Lowry et al.
Protein measurement with the Folin phenol reagent
J Biol Chem
(1951)
EM Southern
Detection of specific sequences among DNA fragments separated by gel eleclrophoreses
J Mol Biol
(1975)
H Williams et al.
First trimester fetal sexing in a pregnancy at risk for Duchenne muscular dystrophy
Lancet
(1983)
Z Kazy et al.
Chorion biopsy in early pregnancy: a method of eurlv prenatal diagnosis for inherited disorders
Prenat Diagn
(1981)

There are more references available in the full text version of this article.

Cited by (15)

Enzymatic Diagnosis of Sphingolipidoses
1987, Methods in Enzymology
The sphingolipidoses are defined as disorders caused by genetic defect in catabolism of sphingosine-containing lipids. Recently, the concept of the sphingolipidoses has been expanded to include a group of genetic disorders caused by defective or absent activator proteins that are normally required for in vivo hydrolysis of the hydrophobic substrates by the hydrolases. This chapter focuses only on those disorders that are because of genetic deficiencies of sphingolipid hydrolases. The only exception is the recently defined galactosialidosis. This disorder established another new category of the sphingolipidoses, being because of a genetic defect in the “protective protein” rather than lysosomal hydrolases. The chapter includes galactosialidosis, the disease that can be diagnosed by assays of appropriate lysosomal hydrolases, even though the genetic defect resides elsewhere. Patients affected by the sphingolipidoses can be diagnosed definitively by appropriate enzyme assays, and heterozygous carriers can be identified in most instances with reasonable reliability. Affected fetuses can also be diagnosed during pregnancy either with cultured amniotic fluid cells or with biopsied chorionic villi. The enzymatic diagnostic procedures described in the chapter may not necessarily be the best procedures for the respective enzymes. The procedures described in this chapter are adequate for typical cases, but are likely to be too simplistic to cope with unusual enzymatic variants. The rapid progress in recent years of the molecular biological technology is beginning to replace some of the enzymatic diagnostic procedures with those based on DNA.
CHORION BIOPSY FOR PRENATAL TESTING IN HUNTER'S SYNDROME
1984, The Lancet
Mitochondrial tRNA<sup>Leu(UUR)</sup> mutation m.3302A>G presenting as childhood-onset severe myopathy: Threshold determination through segregation study
2010, Journal of Inherited Metabolic Disease
Clinical consequences of an increasing trend of preferential use of cultured villi for molecular diagnosis by CVS
2008, Prenatal Diagnosis
First‐trimester biochemical and molecular diagnoses using chorionic villi: High accuracy in the U.S. collaborative study
1992, Prenatal Diagnosis
Chorionic villus sampling for prenatal diagnosis in wales using DNA probes—5 years' experience
1990, Prenatal Diagnosis

View all citing articles on Scopus

View full text

DNA and enzyme studies on chorionic villi for use in antenatal diagnosis

Abstract

Lancet

Lancet

Lancet

Clin Chim Acta

J Biol Chem

J Mol Biol

Lancet

Chorion biopsy in early pregnancy: a method of eurlv prenatal diagnosis for inherited disorders

Prenat Diagn